Athersys and Chugai Pharmaceutical have announced a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan Read the full story

Athersys and Chugai Pharmaceutical have announced a partnership and pharma licensing agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan. Read the full story

Chugai Pharmaceutical signed an agreement with EpiVax to incorporate EpiVax’s ISPRI immunogenicity screening and deimmunization technology into Chugai’s drug development toolbox. Read the full story

Roche had business merger rumors to buy Tokyo-based Chugai Pharmaceutical Co., Ltd. appear to be tabled for now. Sources in Roche indicated the company was focused on its $8.3 billion acquisition of California-based InterMune Inc.

Read the full story

The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story

This report provides all the information you require to better understand Chugai and its partnering interests and activities over the past seven years. Read the full story

Chugai,a top biopharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story

Chugai has paid an upfront payment to Romark, and will make additional payments based on the achievement of certain clinical and regulatory milestones. Romark will participate in profits from product sales in Japan through a supply agreement and royalties.

Chiome and Chugai will develop novel value-added therapeutic monoclonal antibodies employing Chiome’s ADLib® (Autonomously Diversifying Library) System and will apply the System to assessment of target proteins and lead generation of products for clinical use. Read the full story